There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stereotaxis (STXS – Research Report), Capricor Therapeutics (CAPR – Research Report) and ACELYRIN, INC. (SLRN – Research Report) with bullish sentiments.
Stereotaxis (STXS)
In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Stereotaxis, with a price target of $4.00. The company’s shares closed last Monday at $2.16.
According to TipRanks.com, Maeder is a 5-star analyst with an average return of
Stereotaxis has an analyst consensus of Strong Buy, with a price target consensus of $4.33, representing a 98.6% upside. In a report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
Capricor Therapeutics (CAPR)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Capricor Therapeutics yesterday and set a price target of $8.00. The company’s shares closed last Monday at $5.44.
According to TipRanks.com, Kluska is a 5-star analyst with an average return of
Capricor Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $21.25, representing a 297.9% upside. In a report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $25.00 price target.
ACELYRIN, INC. (SLRN)
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on ACELYRIN, INC., with a price target of $68.00. The company’s shares closed last Monday at $4.69, close to its 52-week low of $4.14.
According to TipRanks.com, Rahimi is a 3-star analyst with an average return of
ACELYRIN, INC. has an analyst consensus of Moderate Buy, with a price target consensus of $24.20, implying a 418.2% upside from current levels. In a report issued on May 9, H.C. Wainwright also maintained a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STXS:
- Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies
- Stereotaxis Reports 2024 First Quarter Financial Results
- STXS Earnings this Week: How Will it Perform?
- Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
- Stereotaxis management to meet with Lake Street
